{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:30:36Z","timestamp":1788849036683,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00327"],"award-info":[{"award-number":["PI18\/00327"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP18\/00011"],"award-info":[{"award-number":["CP18\/00011"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/01019"],"award-info":[{"award-number":["PI17\/01019"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","award":["20141210"],"award-info":[{"award-number":["20141210"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2017 SGR 547"],"award-info":[{"award-number":["2017 SGR 547"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Neurodegenerativas","award":["Programa 1. Alzheimer's disease"],"award-info":[{"award-number":["Programa 1. Alzheimer's disease"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>There is an urgent need for objective markers of Alzheimer\u2019s disease (AD)-related cognitive impairment in people with Down syndrome (DS) to improve diagnosis, monitor disease progression, and assess response to disease-modifying therapies. Previously, GluA4 and neuronal pentraxin 2 (NPTX2) showed limited potential as cerebrospinal fluid (CSF) markers of cognitive impairment in adults with DS. Here, we compare the CSF profile of a panel of synaptic proteins (Calsyntenin-1, Neuroligin-2, Neurexin-2A, Neurexin-3A, Syntaxin-1B, Thy-1, VAMP-2) to that of NPTX2 and GluA4 in a large cohort of subjects with DS across the preclinical and clinical AD continuum and explore their correlation with cognitive impairment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We quantified the synaptic panel proteins by selected reaction monitoring in CSF from 20 non-trisomic cognitively normal controls (mean age 44) and 80 adults with DS grouped according to clinical AD diagnosis (asymptomatic, prodromal AD or AD dementia). We used regression analyses to determine CSF changes across the AD continuum and explored correlations with age, global cognitive performance (CAMCOG), episodic memory (modified cued-recall test; mCRT) and CSF biomarkers, CSF A\u03b2<jats:sub>42:40<\/jats:sub>ratio, CSF A\u03b2<jats:sub>1-42<\/jats:sub>, CSF p-tau, and CSF NFL. P values were adjusted for multiple testing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In adults with DS, VAMP-2 was the only synaptic protein to correlate with episodic memory (delayed recall<jats:italic>adj.p<\/jats:italic>= .04) and age (<jats:italic>adj.p<\/jats:italic>= .0008) and was the best correlate of CSF A\u03b2<jats:sub>42:40<\/jats:sub>(<jats:italic>adj.p<\/jats:italic>= .0001), p-tau (<jats:italic>adj.p &lt;<\/jats:italic>.0001), and NFL (<jats:italic>adj.p &lt;<\/jats:italic>.0001). Compared to controls, mean VAMP-2 levels were lower in asymptomatic adults with DS only (<jats:italic>adj.p<\/jats:italic>= .02). CSF levels of Neurexin-3A, Thy-1, Neurexin-2A, Calysntenin-1, Neuroligin-2, GluA4, and Syntaxin-1B all strongly correlated with NPTX2 (<jats:italic>p<\/jats:italic>&lt; .0001), which was the only synaptic protein to show reduced CSF levels in DS at all AD stages compared to controls (<jats:italic>adj.p<\/jats:italic>&lt; .002).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These data show proof-of-concept for CSF VAMP-2 as a potential marker of synapse degeneration that correlates with CSF AD and axonal degeneration markers and cognitive performance.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13195-021-00861-0","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T18:03:19Z","timestamp":1624903399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome"],"prefix":"10.1186","volume":"13","author":[{"given":"Alberto","family":"Lle\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Carmona-Iragui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Videla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bessy","family":"Benejam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Pegueroles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Barroeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miren","family":"Altuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Valldeneu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Fang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"N\u00fa\u00f1ez-Llaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Querol-Vilaseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f2nia","family":"Sirisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Bejanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Florencia","family":"Iulita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Clarim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Blesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Worley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Alcolea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Fortea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6109-6371","authenticated-orcid":false,"given":"Olivia","family":"Belbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"issue":"1","key":"861_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/jir.12074","volume":"58","author":"M McCarron","year":"2014","unstructured":"McCarron M, McCallion P, Reilly E, Mulryan N. A prospective 14-year longitudinal follow-up of dementia in persons with Down syndrome. J Intellect Disabil Res. 2014;58(1):61\u201370. https:\/\/doi.org\/10.1111\/jir.12074.","journal-title":"J Intellect Disabil Res"},{"issue":"2","key":"861_CR2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3233\/JAD-170624","volume":"61","author":"A Sinai","year":"2018","unstructured":"Sinai A, Mokrysz C, Bernal J, Bohnen I, Bonell S, Courtenay K, et al. Predictors of Age of Diagnosis and Survival of Alzheimer\u2019s disease in Down syndrome. J Alzheimers Dis. 2018;61(2):717\u201328. https:\/\/doi.org\/10.3233\/JAD-170624.","journal-title":"J Alzheimers Dis"},{"key":"861_CR3","doi-asserted-by":"crossref","unstructured":"Hithersay R, Startin CM, Hamburg S, Mok KY, Hardy J, Fisher EMC, et al. Association of dementia with mortality among adults with Down syndrome older than 35\u2009years. JAMA Neurol. 2018.","DOI":"10.1001\/jamaneurol.2018.3616"},{"key":"861_CR4","doi-asserted-by":"crossref","unstructured":"Fortea J, Vilaplana E, Carmona-Iragui M, Benejam B, Videla L, Barroeta I, et al. Clinical and biomarker changes of Alzheimer\u2019s disease in adults with Down Syndrome: a cross-sectional study. Lancet. (in press 2020).","DOI":"10.1016\/S0140-6736(20)30689-9"},{"issue":"5594","key":"861_CR5","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1126\/science.1074069","volume":"298","author":"DJ Selkoe","year":"2002","unstructured":"Selkoe DJ. Alzheimer\u2019s disease is a synaptic failure. Science. 2002;298(5594):789\u201391. https:\/\/doi.org\/10.1126\/science.1074069.","journal-title":"Science."},{"issue":"4","key":"861_CR6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572\u201380. https:\/\/doi.org\/10.1002\/ana.410300410.","journal-title":"Ann Neurol"},{"issue":"2","key":"861_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00401-017-1797-4","volume":"135","author":"CM Henstridge","year":"2018","unstructured":"Henstridge CM, Sideris DI, Carroll E, Rotariu S, Salomonsson S, Tzioras M, et al. Synapse loss in the prefrontal cortex is associated with cognitive decline in amyotrophic lateral sclerosis. Acta Neuropathol. 2018;135(2):213\u201326. https:\/\/doi.org\/10.1007\/s00401-017-1797-4.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"861_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1750-1326-6-63","volume":"6","author":"RM Koffie","year":"2011","unstructured":"Koffie RM, Hyman BT, Spires-Jones TL. Alzheimer\u2019s disease: synapses gone cold. Mol Neurodegener. 2011;6(1):63. https:\/\/doi.org\/10.1186\/1750-1326-6-63.","journal-title":"Mol Neurodegener"},{"issue":"Pt 9","key":"861_CR9","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1093\/brain\/awu190","volume":"137","author":"JL Robinson","year":"2014","unstructured":"Robinson JL, Molina-Porcel L, Corrada MM, Raible K, Lee EB, Lee VM, et al. Perforant path synaptic loss correlates with cognitive impairment and Alzheimer\u2019s disease in the oldest-old. Brain. 2014;137(Pt 9):2578\u201387. https:\/\/doi.org\/10.1093\/brain\/awu190.","journal-title":"Brain."},{"issue":"9","key":"861_CR10","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/nn.2621","volume":"13","author":"MC Chang","year":"2010","unstructured":"Chang MC, Park JM, Pelkey KA, Grabenstatter HL, Xu D, Linden DJ, et al. Narp regulates homeostatic scaling of excitatory synapses on parvalbumin-expressing interneurons. Nat Neurosci. 2010;13(9):1090\u20137. https:\/\/doi.org\/10.1038\/nn.2621.","journal-title":"Nat Neurosci"},{"key":"861_CR11","doi-asserted-by":"publisher","unstructured":"Xiao MF, Xu D, Craig MT, Pelkey KA, Chien CC, Shi Y, et al. NPTX2 and cognitive dysfunction in Alzheimer\u2019s disease. Elife. 2017;6. https:\/\/doi.org\/10.7554\/eLife.23798.","DOI":"10.7554\/eLife.23798"},{"key":"861_CR12","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.trci.2019.11.002","volume":"5","author":"DR Galasko","year":"2019","unstructured":"Galasko DR, Xiao M, Xu D, Smirnov D, Salmon DP, Dewit N, et al. Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer\u2019s disease. Alzheimers Dement. 2019;5:871\u201382. https:\/\/doi.org\/10.1016\/j.trci.2019.11.002.","journal-title":"Alzheimers Dement"},{"key":"861_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.bbi.2016.07.148","volume":"58","author":"A Swanson","year":"2016","unstructured":"Swanson A, Willette AA. Neuronal Pentraxin 2 predicts medial temporal atrophy and memory decline across the Alzheimer\u2019s disease spectrum. Brain Behav Immun. 2016;58:201\u20138. https:\/\/doi.org\/10.1016\/j.bbi.2016.07.148.","journal-title":"Brain Behav Immun"},{"key":"861_CR14","doi-asserted-by":"crossref","unstructured":"Shao K, Shan S, Ru W, Ma C. Association between serum NPTX2 and cognitive function in patients with vascular dementia. Brain Behav. 2020:e01779.","DOI":"10.1002\/brb3.1779"},{"issue":"6","key":"861_CR15","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1136\/jnnp-2019-322493","volume":"91","author":"EL van der Ende","year":"2020","unstructured":"van der Ende EL, Xiao M, Xu D, Poos JM, Panman JL, Jiskoot LC, et al. Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2020;91(6):612\u201321. https:\/\/doi.org\/10.1136\/jnnp-2019-322493.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"861_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13024-020-00388-2","volume":"15","author":"I van Steenoven","year":"2020","unstructured":"van Steenoven I, Koel-Simmelink MJA, Vergouw LJM, Tijms BM, Piersma SR, Pham TV, et al. Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. Mol Neurodegener. 2020;15(1):36. https:\/\/doi.org\/10.1186\/s13024-020-00388-2.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"861_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13024-020-00398-0","volume":"15","author":"O Belbin","year":"2020","unstructured":"Belbin O, Xiao MF, Xu D, Carmona-Iragui M, Pegueroles J, Benejam B, et al. Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer\u2019s disease-related inhibitory circuit dysfunction in adults with Down syndrome. Mol Neurodegener. 2020;15(1):46. https:\/\/doi.org\/10.1186\/s13024-020-00398-0.","journal-title":"Mol Neurodegener"},{"issue":"3","key":"861_CR18","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1074\/mcp.RA118.001290","volume":"18","author":"A Lleo","year":"2019","unstructured":"Lleo A, Nunez-Llaves R, Alcolea D, Chiva C, Balateu-Panos D, Colom-Cadena M, et al. Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer\u2019s disease cerebrospinal fluid. Mol Cell Proteomics. 2019;18(3):546\u201360. https:\/\/doi.org\/10.1074\/mcp.RA118.001290.","journal-title":"Mol Cell Proteomics"},{"issue":"1","key":"861_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.trci.2019.09.005","volume":"5","author":"D Alcolea","year":"2019","unstructured":"Alcolea D, Clarimon J, Carmona-Iragui M, Illan-Gala I, Morenas-Rodriguez E, Barroeta I, et al. The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: a data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimers Dement. 2019;5(1):597\u2013609. https:\/\/doi.org\/10.1016\/j.trci.2019.09.005.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"861_CR20","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S1474-4422(18)30285-0","volume":"17","author":"J Fortea","year":"2018","unstructured":"Fortea J, Carmona-Iragui M, Benejam B, Fernandez S, Videla L, Barroeta I, et al. Plasma and CSF biomarkers for the diagnosis of Alzheimer\u2019s disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol. 2018;17(10):860\u20139. https:\/\/doi.org\/10.1016\/S1474-4422(18)30285-0.","journal-title":"Lancet Neurol"},{"issue":"9","key":"861_CR21","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/acn3.50873","volume":"6","author":"D Alcolea","year":"2019","unstructured":"Alcolea D, Pegueroles J, Munoz L, Camacho V, Lopez-Mora D, Fernandez-Leon A, et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer\u2019s disease on Lumipulse. Ann Clin Transl Neurol. 2019;6(9):1815\u201324. https:\/\/doi.org\/10.1002\/acn3.50873.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"861_CR22","doi-asserted-by":"publisher","first-page":"e12047","DOI":"10.1002\/dad2.12047","volume":"12","author":"B Benejam","year":"2020","unstructured":"Benejam B, Videla L, Vilaplana E, Barroeta I, Carmona-Iragui M, Altuna M, et al. Diagnosis of prodromal and Alzheimer\u2019s disease dementia in adults with Down syndrome using neuropsychological tests. Alzheimers Dement (Amst). 2020;12(1):e12047. https:\/\/doi.org\/10.1002\/dad2.12047.","journal-title":"Alzheimers Dement (Amst)"},{"key":"861_CR23","volume-title":"L. Manual for the Kaufman Brief Intelligence Test. : Circle Pines","author":"AS Kaufman","year":"1990","unstructured":"Kaufman AS, Kaufman N. L. Manual for the Kaufman Brief Intelligence Test. : Circle Pines. MN: American Guidance Service; 1990."},{"issue":"8","key":"861_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.33588\/rn.5708.2013259","volume":"57","author":"S Esteba-Castillo","year":"2013","unstructured":"Esteba-Castillo S, Dalmau-Bueno A, Ribas-Vidal N, Vila-Alsina M, Novell-Alsina R, Garcia-Alba J. Adaptation and validation of CAMDEX-DS (Cambridge Examination for Mental Disorders of Older People with Down\u2019s Syndrome and others with intellectual disabilities) in Spanish population with intellectual disabilities. Rev Neurol. 2013;57(8):337\u201346. https:\/\/doi.org\/10.33588\/rn.5708.2013259.","journal-title":"Rev Neurol"},{"issue":"Pt 6","key":"861_CR25","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1046\/j.1365-2788.2002.00417.x","volume":"46","author":"DA Devenny","year":"2002","unstructured":"Devenny DA, Zimmerli EJ, Kittler P, Krinsky-McHale SJ. Cued recall in early-stage dementia in adults with Down\u2019s syndrome. J Intellect Disabil Res. 2002;46(Pt 6):472\u201383. https:\/\/doi.org\/10.1046\/j.1365-2788.2002.00417.x.","journal-title":"J Intellect Disabil Res"},{"issue":"6","key":"861_CR26","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1352\/1944-7558-120.6.481","volume":"120","author":"B Benejam","year":"2015","unstructured":"Benejam B, Fortea J, Molina-Lopez R, Videla S. Patterns of performance on the modified cued recall test in Spanish adults with Down syndrome with and without dementia. Am J Intellect Dev Disabil. 2015;120(6):481\u20139. https:\/\/doi.org\/10.1352\/1944-7558-120.6.481.","journal-title":"Am J Intellect Dev Disabil"},{"key":"861_CR27","first-page":"246412","volume":"2011","author":"CE Teunissen","year":"2011","unstructured":"Teunissen CE, Tumani H, Bennett JL, Berven FS, Brundin L, Comabella M, et al. Consensus guidelines for CSF and blood biobanking for CNS biomarker studies. Mult Scler Int. 2011;2011:246412.","journal-title":"Mult Scler Int"},{"issue":"7","key":"861_CR28","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1212\/WNL.0000000000001859","volume":"85","author":"D Alcolea","year":"2015","unstructured":"Alcolea D, Martinez-Lage P, Sanchez-Juan P, Olazaran J, Antunez C, Izagirre A, et al. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology. 2015;85(7):626\u201333. https:\/\/doi.org\/10.1212\/WNL.0000000000001859.","journal-title":"Neurology."},{"issue":"17","key":"861_CR29","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1093\/bioinformatics\/btu305","volume":"30","author":"M Choi","year":"2014","unstructured":"Choi M, Chang CY, Clough T, Broudy D, Killeen T, MacLean B, et al. MSstats: an R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments. Bioinformatics. 2014;30(17):2524\u20136. https:\/\/doi.org\/10.1093\/bioinformatics\/btu305.","journal-title":"Bioinformatics."},{"key":"861_CR30","volume-title":"R: A language and environment for statistical computing","author":"R-Core-Team","year":"2018","unstructured":"R-Core-Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2018."},{"issue":"1","key":"861_CR31","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1471-2202-12-118","volume":"12","author":"V Benagiano","year":"2011","unstructured":"Benagiano V, Lorusso L, Flace P, Girolamo F, Rizzi A, Bosco L, et al. VAMP-2, SNAP-25A\/B and syntaxin-1 in glutamatergic and GABAergic synapses of the rat cerebellar cortex. BMC Neurosci. 2011;12(1):118. https:\/\/doi.org\/10.1186\/1471-2202-12-118.","journal-title":"BMC Neurosci"},{"issue":"5","key":"861_CR32","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0896-6273(00)80399-2","volume":"19","author":"RC Lin","year":"1997","unstructured":"Lin RC, Scheller RH. Structural organization of the synaptic exocytosis core complex. Neuron. 1997;19(5):1087\u201394. https:\/\/doi.org\/10.1016\/S0896-6273(00)80399-2.","journal-title":"Neuron."},{"key":"861_CR33","doi-asserted-by":"crossref","unstructured":"Gu Y, Chiu SL, Liu B, Wu PH, Delannoy M, Lin DT, et al. Differential vesicular sorting of AMPA and GABAA receptors. Proc Natl Acad Sci U S A. 2016.","DOI":"10.1073\/pnas.1525726113"},{"issue":"10","key":"861_CR34","doi-asserted-by":"publisher","first-page":"e0140868","DOI":"10.1371\/journal.pone.0140868","volume":"10","author":"S Hussain","year":"2015","unstructured":"Hussain S, Davanger S. Postsynaptic VAMP\/synaptobrevin facilitates differential vesicle trafficking of GluA1 and GluA2 AMPA receptor subunits. PLoS One. 2015;10(10):e0140868. https:\/\/doi.org\/10.1371\/journal.pone.0140868.","journal-title":"PLoS One"},{"issue":"6","key":"861_CR35","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.neurobiolaging.2012.11.024","volume":"34","author":"NC Berchtold","year":"2012","unstructured":"Berchtold NC, Coleman PD, Cribbs DH, Rogers J, Gillen DL, Cotman CW. Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer\u2019s disease. Neurobiol Aging. 2012;34(6):1653\u201361. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2012.11.024.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"861_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3233\/JAD-2010-091150","volume":"22","author":"M Sarazin","year":"2010","unstructured":"Sarazin M, Chauvire V, Gerardin E, Colliot O, Kinkingnehun S, de Souza LC, et al. The amnestic syndrome of hippocampal type in Alzheimer\u2019s disease: an MRI study. J Alzheimers Dis. 2010;22(1):285\u201394. https:\/\/doi.org\/10.3233\/JAD-2010-091150.","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"861_CR37","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/nbt1210-1248","volume":"28","author":"M Uhlen","year":"2010","unstructured":"Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010;28(12):1248\u201350. https:\/\/doi.org\/10.1038\/nbt1210-1248.","journal-title":"Nat Biotechnol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00861-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-021-00861-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00861-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T20:29:25Z","timestamp":1672604965000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-021-00861-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["861"],"URL":"https:\/\/doi.org\/10.1186\/s13195-021-00861-0","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,28]]},"assertion":[{"value":"17 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study (IIBSP-BMS-2018-103) was approved by the local ethics committee (Comit\u00e9 \u00c8tic d\u2019Investigaci\u00f3 Cl\u00ednica, Fundaci\u00f3 de Gesti\u00f3 Sanit\u00e0ria de l\u2019Hospital de la Santa Creu i Sant Pau) and was conducted in accordance with the Declaration of Helsinki. All participants gave their written informed consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Drs Belbin, Lle\u00f3, Fortea, and Alcolea declare a filed patent application (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease) that includes the 9 synaptic proteins evaluated in this study. D.A. participated in advisory boards from Fujirebio-Europe and Roche Diagnostics and received speaker honoraria from Fujirebio-Europe, Nutricia and from Krka Farmac\u00e9utica S.L. J.F participated in advisory boards from AC-Immune and was consultant to Novartis. MX, DX and PW are co-founders of CogNext.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}